SCHEMBL25839459

SCHEMBL25839459

CC(C)c1ccc(N2CCN(C(=O)[C@H](C)O)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PANK3 Q9H999 6/20 0.56
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ MAPT P10636 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ TP53 P04637 2/20 0.54
▸ THRB P10828 1/20 0.54
▸ LMNA P02545 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ TSHR P16473 1/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ CASP6 P55212 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23544877 1.00 PANK3 (0.56) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL23544884 0.89 PANK3 (0.57) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL18039045 0.87 GFER (0.66) SMN1; SMN2MAPTALDH1A1MAPK1TP53
SCHEMBL10169298 0.83 MAPT (0.71) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL10288811 0.83 PANK3 (0.58) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL22854086 0.82 PANK3 (0.57) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL23544871 0.81 MAPT (0.54) SMN1; SMN2MAPTALDH1A1MAPK1LMNA
SCHEMBL20883565 0.81 AKR1C3 (0.67) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL20883570 0.81 PANK3 (0.56) PANK3SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL20251137 0.80 MAPT (0.51) PANK3SMN1; SMN2MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697648-B2 Fused pyrimidine pyridinone compounds as JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697648-B2 Fused pyrimidine pyridinone compounds as JAK inhibitors JAK3, JAK1, JAK2 PANK3 105/4885SMN1; SMN2 3707/4885MAPT 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback